← Pharmacy curriculum
Module 16710 lessonsRxPrep 2023 Chapter 23, reconciled with the 2025 IDSA complicated urinary tract infection guideline, 2019 IDSA asymptomatic bacteriuria guideline, 2023 ACOG pregnancy UTI consensus, current IDSA resistant gram-negative guidance, and current product labeling

Urinary Tract Infections

Localize the syndrome, preserve specimen quality, identify obstruction and devices, choose site-active exposure, shorten therapy safely, and leave asymptomatic bacteriuria untreated outside true exceptions.

01

Separate bladder-confined infection from infection beyond the bladder.

02

Interpret symptoms, urinalysis, culture, blood cultures, and imaging without treating tests alone.

03

Select and dose focused uncomplicated cystitis therapy.

04

Treat pyelonephritis and cUTI with renal-tissue-active exposure and current shorter durations.

05

Use IV-to-oral transition and urinary source control deliberately.

06

Apply asymptomatic bacteriuria treatment exceptions precisely.

07

Screen and treat pregnancy UTI with current trimester and tissue boundaries.

08

Evaluate recurrent UTI before selecting prophylaxis.

09

Prevent and manage catheter-associated infection without treating colonization.

10

Adapt therapy for resistant organisms, allergy, organs, interactions, and stewardship.

167.01

Lesson

Localize the Infection Before Naming It Complicated

Current classification begins with whether symptomatic infection is confined to the bladder or has progressed beyond it. Anatomy and host factors remain essential modifiers.

What to learn
  • Cystitis
  • Pyelonephritis
  • cUTI
  • Obstruction
  • Sepsis
Clinical pathwayLocalize
01BladderDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02KidneyPreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03SystemicMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04SourceOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Identify bladder disease

Dysuria, frequency, urgency, suprapubic discomfort, and hematuria without fever or flank findings support cystitis.

Recognize extension

Fever, flank pain, nausea, vomiting, bacteremia, or systemic illness suggests pyelonephritis or cUTI beyond the bladder.

Update the old sex shortcut

The 2025 IDSA framework does not define cUTI from sex alone. Record prostatitis, obstruction, hardware, pregnancy, and host risk separately.

Decompress danger

An infected obstructed collecting system, abscess, emphysematous disease, or blocked device requires urgent urologic control with resuscitation and antibiotics.

Quick check

0 of 1 answered
01Which finding most strongly indicates infection beyond the bladder?
Answer every question to submit.
167.02

Lesson

Treat a Syndrome, Not a Urine Result

Symptoms establish the clinical problem. Urinalysis, culture, blood cultures, and imaging support specific decisions when specimen quality is reliable.

What to learn
  • Symptoms
  • Pyuria
  • Nitrites
  • Culture
  • Imaging
Clinical pathwayVerify
01SymptomsDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02UrinalysisPreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03CultureMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04ImagingOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Use urinalysis as support

Pyuria is sensitive but nonspecific. Nitrites are specific when present but absent with some pathogens or frequent voiding.

Culture higher-risk disease

Culture pyelonephritis, cUTI, pregnancy, recurrence, failure, resistant risk, and cases in which susceptibility will alter therapy.

Protect specimen quality

Use a clean-catch or appropriate fresh-catheter specimen and interpret mixed growth, squamous cells, colony count, symptoms, and prior antibiotics together.

Image a source question

Use ultrasound or CT for obstruction, stone, abscess, unusual organism, recurrence, severe illness, or lack of prompt response, with pregnancy-appropriate adaptation.

Quick check

0 of 1 answered
01What does pyuria establish in an asymptomatic patient?
Answer every question to submit.
167.03

Lesson

Match Bladder Therapy to the Patient and Organism

Focused lower-tract regimens reduce collateral harm when localization, kidney function, resistance, allergy, and pregnancy are addressed.

What to learn
  • Nitrofurantoin
  • TMP-SMX
  • Fosfomycin
  • Beta-lactams
  • Fluoroquinolone reserve
Clinical pathwayFocus
01NitrofurantoinDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02TMP-SMXPreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03FosfomycinMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04ReserveOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Use nitrofurantoin correctly

Nitrofurantoin monohydrate and macrocrystals 100 mg orally twice daily with food for five days is a standard option when renal function and safety permit. It does not treat pyelonephritis.

Gate TMP-SMX by resistance

Use DS 160/800 mg orally twice daily for three days when susceptibility or local E. coli resistance below 20 percent supports empiric use and patient risks permit.

Understand fosfomycin

Fosfomycin tromethamine 3 g orally once can treat selected bladder infection but has organism and efficacy boundaries and does not treat renal parenchymal disease.

Reserve broader agents

Use beta-lactams from susceptibility when appropriate. Preserve fluoroquinolones for situations in which benefits outweigh tendon, nerve, CNS, glycemic, aortic, QT, and ecological risks.

Quick check

0 of 1 answered
01Which regimen is standard for eligible uncomplicated cystitis?
Answer every question to submit.
167.04

Lesson

Use Current Short Courses After Effective Therapy Begins

The 2025 IDSA cUTI update replaces the routine 10 to 14 day default for improving eligible patients.

What to learn
  • Tissue penetration
  • Culture
  • Five to seven days
  • Seven days
  • Bacteremia
Clinical pathwayTreat tissue
01CultureDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02Active day onePreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03Short courseMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04ResponseOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Ensure renal-tissue activity

Nitrofurantoin and oral fosfomycin do not reach adequate renal parenchymal concentrations. Choose from susceptibility, illness, local resistance, and oral feasibility.

Shorten fluoroquinolones

Use 5 to 7 days of an effective fluoroquinolone for improving eligible cUTI or acute pyelonephritis.

Shorten other agents

Use seven days of an effective nonfluoroquinolone in improving eligible patients rather than 10 to 14 days.

Individualize exclusions

Catheters, severe sepsis, immune compromise, abscess, CKD, bacterial prostatitis, complete obstruction, and urologic procedures were often excluded from supporting studies.

Quick check

0 of 1 answered
01What duration is suggested for improving eligible cUTI treated with an effective nonfluoroquinolone?
Answer every question to submit.
167.05

Lesson

Remove the Nidus and Let Route Follow Exposure

IV therapy is not a badge of severity. Obstruction and retained devices matter more than the route once active oral exposure is reliable.

What to learn
  • IV-to-oral
  • Obstruction
  • Catheter
  • Abscess
  • Failure
Clinical pathwayControl
01DrainDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02Remove devicePreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03Switch routeMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04ReassessOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Switch on evidence

Use an active, bioavailable oral agent when the patient improves, can absorb and adhere, has source control, and has no unresolved syndrome requiring IV exposure.

Control obstruction

Drain an infected obstructed system urgently. Remove or exchange unnecessary or long-standing devices when indicated and culture from a meaningful new specimen.

Count active days

For resistant organisms or initially inactive therapy, count the course from initiation of an effective agent when the syndrome requires it.

Investigate failure

Persistent fever or pain requires imaging, culture, dose and adherence review, obstruction assessment, prostatitis evaluation, and reconsideration of the diagnosis.

Quick check

0 of 1 answered
01What is essential in pyelonephritis with an obstructed collecting system and shock?
Answer every question to submit.
167.06

Lesson

Protect Patients From Treating Colonization

Bacteriuria with or without pyuria is common. Without attributable symptoms, most populations receive no benefit from antibiotics.

What to learn
  • ASB
  • Pregnancy
  • Endourologic procedure
  • Older adults
  • Stewardship
Clinical pathwayDo not treat a test
01SymptomsDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02PregnancyPreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03ProcedureMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04ObserveOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Define ASB

Significant bacteriuria without urinary symptoms is ASB irrespective of pyuria.

Use narrow exceptions

Screen and treat pregnancy and selected endourologic procedures involving mucosal trauma. Do not extend the exception to clean nonurologic surgery.

Do not treat common colonization

Healthy nonpregnant adults, older adults, diabetes, chronic catheters, spinal cord injury, and most transplant contexts should not be screened or treated routinely.

Reframe delirium and falls

Without urinary symptoms, fever, or instability, assess medications, hydration, pain, injury, metabolic, neurologic, and other infectious causes instead of treating the culture.

Quick check

0 of 1 answered
01Who should be screened and treated for asymptomatic bacteriuria?
Answer every question to submit.
167.07

Lesson

Protect Maternal Renal Health Without Inventing Trimester Absolutes

Pregnancy changes screening, duration, drug safety, tissue penetration, and disposition. Decisions use narrative risk rather than old pregnancy letters.

What to learn
  • Early culture
  • ASB
  • Cystitis
  • Pyelonephritis
  • Suppression
Clinical pathwayProtect two patients
01ScreenDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02TargetPreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03LocalizeMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04EscalateOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Screen once early

Obtain one urine culture early in prenatal care. Treat ASB for 4 to 7 days with the shortest effective course for the selected agent.

Treat cystitis for 5 to 7 days

Obtain culture and avoid empiric ampicillin or amoxicillin because E. coli resistance is high. Nitrofurantoin, beta-lactams, sulfonamides, or fosfomycin can fit selected patients.

Use nuanced trimester safety

Nitrofurantoin and sulfonamides can be reasonable in the first trimester when no appropriate alternative exists and can be first-line later, with G6PD and near-delivery risks considered.

Admit pyelonephritis initially

Begin parenteral renal-tissue-active therapy, monitor maternal and fetal status, sepsis, ARDS, and obstruction, then tailor to culture. Do not use nitrofurantoin or fosfomycin for possible upper-tract infection.

Quick check

0 of 1 answered
01Which agents should be avoided when pregnancy pyelonephritis is possible?
Answer every question to submit.
167.08

Lesson

Prove Recurrence Before Prescribing Prevention

Recurrent symptoms can represent reinfection, relapse, stones, retention, pelvic-floor disease, vaginitis, interstitial cystitis, or another diagnosis.

What to learn
  • Episode confirmation
  • Relapse
  • Reinfection
  • Prophylaxis
  • Vaginal estrogen
Clinical pathwayFind the pattern
01ConfirmDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02NidusPreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03PreventMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04ShareOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Confirm the pattern

Use symptom history and cultures when appropriate to distinguish recurrence from persistent noninfectious urinary symptoms.

Find a nidus

Repeated same-organism infection, rapid relapse, hematuria, stones, retention, or unusual pathogens can justify imaging or urologic evaluation.

Individualize prophylaxis

Use patient-initiated, postcoital, or daily low-dose regimens only after documented recurrence, susceptibility review, toxicity assessment, and preference.

Use nonantibiotic prevention

Address hydration when safe, delayed voiding, spermicides, postmenopausal vaginal estrogen when appropriate, retention, and unnecessary catheters.

Quick check

0 of 1 answered
01What should happen before long-term prophylaxis for recurrent UTI?
Answer every question to submit.
167.09

Lesson

Remove the Device Risk Before Treating the Bag

Catheters create bacteriuria over time. Cloudiness, odor, sediment, pyuria, and positive cultures do not independently diagnose CAUTI.

What to learn
  • Indication
  • Closed drainage
  • Symptoms
  • Exchange
  • Phenazopyridine
Clinical pathwayReduce devices
01IndicationDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02Closed flowPreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03SymptomsMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04RemoveOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Prevent first

Use an indication, aseptic insertion, closed drainage, unobstructed flow, correct bag position, and daily removal ownership.

Diagnose clinically

Require compatible urinary or systemic findings with no better source. Do not culture or treat cloudy or odorous urine alone.

Manage the catheter

Remove it when no longer needed. When appropriate, exchange a long-standing catheter before culture and treatment so biofilm and specimen quality are addressed.

Limit phenazopyridine

Use 200 mg orally three times daily after meals for no more than two days when kidney and liver function permit. Counsel about orange-red urine and body-fluid staining.

Quick check

0 of 1 answered
01What should be done for cloudy urine in an asymptomatic chronic-catheter user?
Answer every question to submit.
167.10

Lesson

Close the Regimen Around the Whole Patient

Susceptibility, resistance mechanism, site, organ function, allergy, interactions, pregnancy, route, source control, and stop ownership form one prescription.

What to learn
  • ESBL
  • CRE
  • Allergy
  • Kidney function
  • Stop date
Clinical pathwayClose the plan
01MechanismDefine the syndrome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

02SitePreserve the evidence

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

03ExposureMatch exposure

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

04StopOwn the outcome

Connect this decision to anatomy, patient risk, source control, and the next reassessment.

Use current resistance guidance

Apply current IDSA pathways for ESBL, AmpC, CRE, and difficult-to-treat Pseudomonas while preserving oral options when susceptible and site-appropriate.

Do not lengthen for resistance alone

A resistant phenotype changes drug selection, not duration by itself. Use the same syndrome and response framework when effective therapy and source control are present.

Recalculate safety

Clarify allergy and follow kidney trajectory, dialysis, potassium, QT, G6PD, tendon and nerve risk, warfarin, RAAS drugs, and pregnancy.

Document closeout

Name syndrome, organism, active day one, source control, oral criteria, total stop date, pending-result owner, adverse-effect plan, and return signs.

Quick check

0 of 1 answered
01Does an ESBL phenotype automatically require a longer cUTI duration?
Answer every question to submit.

Module test

Check the connections.

Each attempt draws 10 questions from the complete 130 question bank.

130 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

References

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. IDSA 2025 Complicated UTI Guideline
  2. IDSA Asymptomatic Bacteriuria Guideline
  3. ACOG UTI in Pregnancy Consensus
  4. IDSA Resistant Gram-Negative Guidance
PharmacyOpen tools